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Despite numerous advances in health care practices, cardio-
vascular disease still remains the leading cause of morbidity
andmortalityworldwide.Perhapsthemostimportantconse-
quence of cardiovascular disease is the interruption of blood
ﬂow to organs such as the heart and brain, resulting in the
clinical presentation of a heart attack or stroke. As such, the
regulation of vascular tone and the maintenance of vascular
patency are vital for the preservation of cardiovascular
health. Central to this process is the vascular endothelium.
The endothelium is vital for the regulation of vascular tone
and the maintenance of vascular homeostasis, as it releases
factors such as nitric oxide, hydrogen sulﬁde, endothelial-
dependent hyperpolarizing factor, and prostacyclin that
induce vasodilatation and keep the vasculature free of
obstructions [1]. Therefore, it should be of no surprise that
a number of the risk factors for the development of cardio-
vasculardisease,suchashypertension,hypercholesterolemia,
diabetes, smoking, ageing, and atherosclerosis, correlate with
an impaired endothelium [2]. This impairment, termed
endothelial dysfunction, is characterized by the reduction in
the bioavailability of vasodilators, particularly nitric oxide,
and/or an increase in endothelium-derived contracting fac-
tors [3]. The resulting imbalance leads to an impairment
of endothelium-dependent vasodilation, as well as a com-
promised state of endothelial activation characterized by
proinﬂammatory, proliferative, and procoagulatory condi-
tions that favor all stages of atherogenesis [4]. Therefore, it
is critically important to develop and implement therapeutic
strategies that will combat endothelial dysfunction in an
eﬀort to reduce the mortality and morbidity associated with
cardiovascular diseases. However, before therapeutic strate-
giescanbeimplementeditisimportanttohaveaclearunder-
standing of the pathological mechanisms that lead to the en-
dothelial dysfunction in the ﬁrst place.
This special issue of highlights the latest ﬁndings related
to the role of endothelial dysfunction in cardiovascular dis-
ease and comprises ﬁve review articles and one original re-
port. The ﬁrst three articles share the common theme of
endothelialdysfunctionindiabetes.Eachpaperoﬀersunique
insights into the mechanisms underlying diabetes-induced
changes in endothelial biology and highlights speciﬁc path-
ways that could be novel therapeutic targets.
The review article in this series by S. D. Funk et al. dis-
cussesthemechanismsthatcontributetothedevelopmentof
atherosclerosis in diabetics. This paper highlights the central
role of hyperglycemia in promoting endothelial dysfunction
anddiscusseshowcellularandanimalstudieshavetranslated
to clinical development of therapeutics targeting endothelial
dysfunction in diabetes. The next paper by A. Sharma et
al. highlights the importance of alterations in endothelium-
derived nitric oxide (EDNO) production in the pathogenesis
of vascular complications in both type 1 and type 2 diabetes.
The interrelationship between reactive oxygen species (ROS)
and EDNO is described, with emphasis on the cellular
and molecular mechanisms that give rise to altered NO
bioavailability in diabetes. In their paper, G. K. Kolluru et al.
emphasize the importance of angiogenesis in diabetes and
chronicle studies that have yielded mechanistic insights into2 International Journal of Vascular Medicine
the development of endothelial dysfunction in diabetes. This
comprehensive paper, entitled “Endothelial dysfunction and
diabetes: eﬀects on angiogenesis, vascular remodeling, and
wound healing,” discusses how ROS and deﬁciencies in NO
bioavailability contribute to altered angiogenesis in diabetes.
Therapeutic management of angiogenesis in diabetes is also
discussed.
In another review article in this series, M. Murakami
provides a comprehensive overview of the mechanisms con-
tributing to the active maintenance of the vasculature. The
roleofgrowthfactorsandcytokinesinmediating endothelial
and mural cell maintenance is described, with an analysis of
how genetic alterations in these pathways give rise to blood
vessel abnormalities and susceptibility to vascular disease.
The molecular and cellular mechanisms leading to restenosis
and the potential for new therapeutics targeting vascular
smooth muscle cell (VSMC) proliferation are the topic of
a review article in this series. L. Denes et al. highlight the
importance of VSMC phenotype switching and proliferation
in vascular disease and discuss the clinical diagnosis and
management of restenosis.
The original report by I. Liesmaa et al. is entitled “Brad-
ykinintype-2receptorexpressioncorrelateswithageandissub-
jected to transcriptional regulation.” This study demonstrates
that bradykinin type-2 receptor (BK-2R) mRNA is positively
correlated with age, but is signiﬁcantly reduced in human
patients with idiopathic dilated cardiomyopathy (IDC) com-
pared with healthy individuals. The study further examines
the relationship between polymorphisms in the BK-2R pro-
moter and the presence of IDC and coronary heart disease.
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